Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013–2015)

Pfaller, Michael A.; Shortridge, Dee; Sader, Hélio S.; Gales, Ana Cristina; Castanheira, Mariana; Flamm, Robert K.

doi:10.1016/j.bjid.2017.06.008

Cited by 36 publications

(28 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, a recent report from Australia and New Zealand on 449 clinical isolates (mainly related to bloodstream infections and pneumonia from 2013 and 2105) demonstrated that TOL/TAZ retained good activity against PA strains resistant to ceftazidime, piperacillin/tazobactam, meropenem [8]. Similar results emerged from another report related to four Latin American countries (Argentina, Brazil, Mexico, Chile) over a 3-year period (2013)(2014)(2015) in which 537 PA isolates were collected: TOL/ TAZ inhibited 86.8% of the strains, being the most active betalactam agent [9].…”

Section: Letter To the Editorsupporting

confidence: 70%

Response to: ‘Letter to the Editor: “Management of multidrug-resistant Pseudomonas aeruginosa in the Intensive Care Unit: state of the art”’

Maraolo

Cascella

Corcione

et al. 2018

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Section: Letter To the Editorsupporting

confidence: 70%

Response to: ‘Letter to the Editor: “Management of multidrug-resistant Pseudomonas aeruginosa in the Intensive Care Unit: state of the art”’

Maraolo

Cascella

Corcione

et al. 2018

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

“…As is evident in Fig. 2, the goodness-of-fit plots created for the pediatric population showed 4 6 8…”

Section: Resultsmentioning

confidence: 72%

“…this in vitro activity has also been confirmed against isolates obtained from pediatric patients (2)(3)(4)(5)(6)(7). Ceftolozane-tazobactam, administered every 8 h as a 1-h intravenous (i.v.)…”

mentioning

confidence: 70%

Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections

Larson

Patel

Willavize

et al. 2019

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Ceftolozane-tazobactam, a combination of the novel antipseudomonal cephalosporin ceftolozane and the well-established extended-spectrum ␤-lactamase inhibitor tazobactam, is approved for treating complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) in adults. To determine doses likely to be safe and efficacious in phase 2 pediatric trials for the same indications, single-dose ceftolozane-tazobactam plasma pharmacokinetic data from a recently completed phase 1 trial in pediatric patients (birth to Ͻ18 years old) with proven/suspected Gram-negative bacterial infections, along with pharmacokinetic data from 12 adult studies, were integrated into a population pharmacokinetic (popPK) analysis. Two-compartment linear models with first-order elimination described the concentration-time profiles of ceftolozane and tazobactam in pediatric patients well. Renal function and body weight were identified to be significant predictors of ceftolozane-tazobactam pharmacokinetics. Renal function, as measured by the estimated glomerular filtration rate (eGFR), significantly affected the clearance of both ceftolozane and tazobactam. Body weight significantly affected clearance and the distribution volume, also of both ceftolozane and tazobactam. Patients with infections had a 32.3% lower tazobactam clearance than healthy volunteers. Using the final popPK models, simulations of various dosing regimens were conducted to assess each regimen's plasma exposure and the probability of pharmacokinetic/pharmacodynamic target attainment. Based on these simulations, the following doses are recommended for further clinical evaluation in phase 2 pediatric trials for cUTI and cIAI (in patients with an eGFR of Ն50 ml/min/1.73 m 2 only): for children Ն12 years old, 1.5 g ceftolozane-tazobactam (1 g ceftolozane with 0.5 g tazobactam), and for neonates/very young infants, infants, and children Ͻ12 years old, 20/10 mg/kg of body weight ceftolozane-tazobactam, both via a 1-h intravenous infusion every 8 h.

show abstract

“…The occurrence of CRE has been investigated in many studies includes Huang T et al 26 (Belgium), Baran I et al 27 (Turkey), Mathersa J et al 28 (USA), Pfaller MA et al 29 (Latin America), Partina I et al 30 (Russia), Pfaller MA et al 31 (Australia and New Zealand) and Logan LK et al 32 (USA) which reported the frequency of CRE were 3.46%, 2.8%, 5.7%, 6.6%, 11.6%, 0.1% and 0.08% respectively. 26−32 Also Sader HS et al 33 study were found the occurrence of CRE in Poland, Italy, Greece and Romania were 17.3%, 7.5%, 7.4%, and 5.0% respectively.…”

Section: Asiamentioning

confidence: 99%

Prevalence and antibiotics susceptibility patterns of carbapenem resistant Enterobacteriaceae

Almugadam¹

2018

JBMOA

View full text Add to dashboard Cite

Understanding the prevalence of CRE is necessary to provide information on the temporal, and geographic occurrence of carbapenem resistance; and the size of this problem in order to facilitate its prevention and control. Base on previously published researches, the prevalence's of CRE among clinical samples were slightly different among different regions in the world. Africa The emergence of CRE has been observed and reported in many studies includes Oduyebo OO et al. 11 (Nigeria), Legese MH et al. 12

show abstract

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013–2015)

Abstract: Ceftolozane-tazobactam was the most active β-lactam agent tested against P. aeruginosa and demonstrated higher in vitro activity than available cephalosporins and piperacillin-tazobactam when tested against Enterobacteriaceae.

Cited by 36 publications

References 17 publications

Response to: ‘Letter to the Editor: “Management of multidrug-resistant Pseudomonas aeruginosa in the Intensive Care Unit: state of the art”’

Response to: ‘Letter to the Editor: “Management of multidrug-resistant Pseudomonas aeruginosa in the Intensive Care Unit: state of the art”’

Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections

Prevalence and antibiotics susceptibility patterns of carbapenem resistant Enterobacteriaceae

Contact Info

Product

Resources

About